IRIS
FERONE, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 35.612
AS - Asia 3.892
NA - Nord America 3.285
Continente sconosciuto - Info sul continente non disponibili 622
SA - Sud America 328
AF - Africa 74
OC - Oceania 4
Totale 43.817
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 34.972
US - Stati Uniti d'America 3.066
SG - Singapore 1.530
CN - Cina 953
VN - Vietnam 614
BD - Bangladesh 432
FR - Francia 296
BR - Brasile 206
HK - Hong Kong 113
FI - Finlandia 109
CA - Canada 78
DE - Germania 59
AR - Argentina 56
GB - Regno Unito 46
MX - Messico 45
JP - Giappone 41
IQ - Iraq 32
JM - Giamaica 27
ID - Indonesia 26
IN - India 25
EC - Ecuador 22
ZA - Sudafrica 19
CH - Svizzera 18
PH - Filippine 17
NL - Olanda 16
ES - Italia 14
IE - Irlanda 14
VE - Venezuela 14
CO - Colombia 13
TH - Thailandia 13
TR - Turchia 13
CR - Costa Rica 12
RU - Federazione Russa 11
SA - Arabia Saudita 11
CL - Cile 10
DZ - Algeria 10
GT - Guatemala 10
HN - Honduras 9
PK - Pakistan 9
NP - Nepal 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
KE - Kenya 7
MA - Marocco 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
UA - Ucraina 7
MY - Malesia 6
PL - Polonia 6
TN - Tunisia 6
LB - Libano 5
NI - Nicaragua 5
SE - Svezia 5
SV - El Salvador 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
RO - Romania 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
AU - Australia 3
BB - Barbados 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
LC - Santa Lucia 3
MU - Mauritius 3
NG - Nigeria 3
NO - Norvegia 3
PE - Perù 3
PR - Porto Rico 3
RS - Serbia 3
AG - Antigua e Barbuda 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
EG - Egitto 2
GR - Grecia 2
HR - Croazia 2
KR - Corea 2
LT - Lituania 2
MM - Myanmar 2
OM - Oman 2
PY - Paraguay 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BZ - Belize 1
CD - Congo 1
CM - Camerun 1
DJ - Gibuti 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
HT - Haiti 1
Totale 43.179
Salva come PNG Salva come JPEG
Città #
Genova 21.519
Genoa 8.348
Rapallo 2.417
Vado Ligure 2.268
San Jose 800
Singapore 709
Ashburn 307
Lauterbourg 272
Ho Chi Minh City 175
New York 147
Hanoi 145
Beijing 144
Council Bluffs 112
Hong Kong 111
Helsinki 95
Santa Clara 92
Los Angeles 58
Frankfurt am Main 45
Milan 43
Chicago 40
Bordighera 39
Tokyo 39
Dallas 35
Rome 35
Haiphong 32
Buffalo 30
Boardman 26
Mexico City 26
Da Nang 25
Orem 24
São Paulo 22
Phoenix 21
Tianjin 18
Atlanta 17
Bologna 17
Naples 17
Newark 17
Turin 17
Zurich 16
Kingston 15
Philadelphia 15
Brooklyn 14
Houston 14
Dublin 13
Lappeenranta 13
Montreal 13
Toronto 13
Cardiff 12
Hamilton 12
London 12
San Francisco 12
Charlotte 11
Guangzhou 11
The Bronx 11
Can Tho 10
Ilion 10
San José 10
Baghdad 9
Biên Hòa 9
Hải Dương 9
Modena 9
Palermo 9
Cleveland 8
Denver 8
Florence 8
Memphis 8
Quito 8
Shanghai 8
Agawam 7
Amman 7
Amsterdam 7
Buenos Aires 7
City of London 7
Columbus 7
Des Moines 7
Garland 7
Guayaquil 7
Johannesburg 7
Miami 7
Nairobi 7
Quận Ba 7
San Antonio 7
Seattle 7
Thái Bình 7
Boston 6
Brescia 6
Corona 6
Guatemala City 6
Jacksonville 6
Jeddah 6
Louisville 6
Maple Grove 6
Ninh Bình 6
Nuremberg 6
Pittsburgh 6
Princeton 6
Queens 6
San Diego 6
San Pedro Sula 6
Warsaw 6
Totale 38.842
Salva come PNG Salva come JPEG
Nome #
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins 323
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 243
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 239
Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. 239
Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system 235
Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care 231
Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New? 226
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 225
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study 224
Acromegaly is associated with increased cancer risk: A survey in Italy 222
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 220
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 214
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 213
Effect of environment on growth: auxological and hormonal parameters in African and Italian children 213
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 211
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. 210
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 207
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 207
Pituitary image: pituicytoma. 205
Computed tomography colonography in acromegaly 205
Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone 197
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 196
Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases 194
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 194
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient 192
Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease 191
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids 191
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study 189
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 189
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 188
(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. 187
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 187
"Present and future of immunotherapy in Neuroendocrine Tumors" 187
Hormone receptors analysis in idiopathic progressive subglottic stenosis 186
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. 186
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management 185
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 185
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas 184
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 184
A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery? 183
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system 182
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. 181
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 180
The pathology of the ulnar nerve in acromegaly. 179
KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment ? 179
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 179
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 178
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. 177
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 175
A pilot study on nerve ultrasound in acromegaly 173
One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients 173
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 173
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 172
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation 171
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. 169
Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor 167
On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-CoV-2 diagnostic 165
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 165
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. 165
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities 164
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 164
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure 163
Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. 163
Somatostatin receptor scintigraphy in thoracic diseases 162
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 162
Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? 162
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 162
Endoscopic endonasal transsphenoidal approach: An additional reason in support of surgery in the management of pituitary lesions. 161
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 161
Doe4s biopsy reliably identify grade in gastro-entero-pancreatic neuroendocrine tumors? 161
Managing Cushing's disease: The state of the art 161
Rare diseases in clinical endocrinology: A taxonomic classification system 161
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 161
Initial staging of lymphoma with octreotide and other receptor imaging agents. 160
Somatostatin receptor ligands in the treatment of acromegaly 160
A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency 160
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 159
Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients 159
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 158
Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments 158
Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. 158
Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly 157
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration. 157
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update 157
Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR 155
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. 155
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. 155
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 155
Dopamine receptor expression and function in corticotroph ectopic tumors. 154
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 154
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 153
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 153
Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency 153
Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. 153
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 153
Sympathovagal imbalance in acromegalic patients 152
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors 152
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 152
Trigger Finger, an Early Musculoskeletal Manifestation of Acromegaly 151
Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells 151
Totale 18.052
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.461
article - articoli 142.180
book - libri 0
conference - conferenze 695
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 586
Totale 286.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.426 98 221 283 437 90 251 257 736 174 317 163 399
2022/20232.958 329 208 39 270 442 524 23 219 531 26 302 45
2023/20241.652 90 221 39 186 131 283 108 69 100 66 100 259
2024/20255.496 153 423 155 368 781 573 564 784 247 267 502 679
2025/202610.587 1.078 332 1.010 921 1.120 1.032 1.611 419 774 889 650 751
2026/20271.176 1.176 0 0 0 0 0 0 0 0 0 0 0
Totale 43.817